Ionis: Euro licensing agreement with Otsuka in hereditary angioedema

 

• Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients
• Ionis plans to independently bring donidalorsen to U.S. patients if approved
• Donidalorsen Phase 3 results expected in the first half of 2024

https://www.prnewswire.com/news-releases/ionis-announces-european-licensing-agreement-with-otsuka-for-donidalorsen-in-hereditary-angioedema-302017888.html